Long-term treatment of glabellar rhytides using onabotulinumtoxina

Roger Dailey, Asha Philip, Greg Tardie

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

OBJECTIVE To determine whether injection every 4 months with onabotulinumtoxinA provides longer-lasting reduction or elimination of glabellar rhytides. METHODS Toxin-naive women (N=45) aged 30 to 50 with moderate to severe glabellar lines at maximum contraction completed the study. Five sites were treated with 4 U of onabotulinumtoxinA. Participants were assessed at day 30; those with glabellar severity of none to mild remained in the study. Participants received identical treatments at months 4, 8, 12, 16, and 20, and were assessed without treatment at 24, 25, and 26 months. RESULTS Baseline physician- and participant-rated treatment responders at maximum contraction were 84% and 80%, respectively, at month 20; and 56% and 58%, respectively, at month 26. Mean changes from physician- and participant-assessed Facial Wrinkle Scale at maximum contraction from baseline to all postbaseline measurements were significant (p≤.001). The percentage of participants reporting neutral (0) to couldn't be more satisfied (+4) with their appearance ranged from 91% to 100% during months 1 to 24. At month 26, 87% of participants reported satisfaction, with appearance scores between 0 and +4. No adverse events were reported. CONCLUSIONS OnabotulinumtoxinA delivered for 20 months significantly reduces or progressively eliminates glabellar rhytides for up to 6 months after the last treatment.

Original languageEnglish (US)
Pages (from-to)918-928
Number of pages11
JournalDermatologic Surgery
Volume37
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Physicians
Therapeutics
Injections
onabotulinumtoxinA

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Long-term treatment of glabellar rhytides using onabotulinumtoxina. / Dailey, Roger; Philip, Asha; Tardie, Greg.

In: Dermatologic Surgery, Vol. 37, No. 7, 07.2011, p. 918-928.

Research output: Contribution to journalArticle

Dailey, Roger ; Philip, Asha ; Tardie, Greg. / Long-term treatment of glabellar rhytides using onabotulinumtoxina. In: Dermatologic Surgery. 2011 ; Vol. 37, No. 7. pp. 918-928.
@article{7f9baad74294453bbbdfde98d28a1968,
title = "Long-term treatment of glabellar rhytides using onabotulinumtoxina",
abstract = "OBJECTIVE To determine whether injection every 4 months with onabotulinumtoxinA provides longer-lasting reduction or elimination of glabellar rhytides. METHODS Toxin-naive women (N=45) aged 30 to 50 with moderate to severe glabellar lines at maximum contraction completed the study. Five sites were treated with 4 U of onabotulinumtoxinA. Participants were assessed at day 30; those with glabellar severity of none to mild remained in the study. Participants received identical treatments at months 4, 8, 12, 16, and 20, and were assessed without treatment at 24, 25, and 26 months. RESULTS Baseline physician- and participant-rated treatment responders at maximum contraction were 84{\%} and 80{\%}, respectively, at month 20; and 56{\%} and 58{\%}, respectively, at month 26. Mean changes from physician- and participant-assessed Facial Wrinkle Scale at maximum contraction from baseline to all postbaseline measurements were significant (p≤.001). The percentage of participants reporting neutral (0) to couldn't be more satisfied (+4) with their appearance ranged from 91{\%} to 100{\%} during months 1 to 24. At month 26, 87{\%} of participants reported satisfaction, with appearance scores between 0 and +4. No adverse events were reported. CONCLUSIONS OnabotulinumtoxinA delivered for 20 months significantly reduces or progressively eliminates glabellar rhytides for up to 6 months after the last treatment.",
author = "Roger Dailey and Asha Philip and Greg Tardie",
year = "2011",
month = "7",
doi = "10.1111/j.1524-4725.2011.02024.x",
language = "English (US)",
volume = "37",
pages = "918--928",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Long-term treatment of glabellar rhytides using onabotulinumtoxina

AU - Dailey, Roger

AU - Philip, Asha

AU - Tardie, Greg

PY - 2011/7

Y1 - 2011/7

N2 - OBJECTIVE To determine whether injection every 4 months with onabotulinumtoxinA provides longer-lasting reduction or elimination of glabellar rhytides. METHODS Toxin-naive women (N=45) aged 30 to 50 with moderate to severe glabellar lines at maximum contraction completed the study. Five sites were treated with 4 U of onabotulinumtoxinA. Participants were assessed at day 30; those with glabellar severity of none to mild remained in the study. Participants received identical treatments at months 4, 8, 12, 16, and 20, and were assessed without treatment at 24, 25, and 26 months. RESULTS Baseline physician- and participant-rated treatment responders at maximum contraction were 84% and 80%, respectively, at month 20; and 56% and 58%, respectively, at month 26. Mean changes from physician- and participant-assessed Facial Wrinkle Scale at maximum contraction from baseline to all postbaseline measurements were significant (p≤.001). The percentage of participants reporting neutral (0) to couldn't be more satisfied (+4) with their appearance ranged from 91% to 100% during months 1 to 24. At month 26, 87% of participants reported satisfaction, with appearance scores between 0 and +4. No adverse events were reported. CONCLUSIONS OnabotulinumtoxinA delivered for 20 months significantly reduces or progressively eliminates glabellar rhytides for up to 6 months after the last treatment.

AB - OBJECTIVE To determine whether injection every 4 months with onabotulinumtoxinA provides longer-lasting reduction or elimination of glabellar rhytides. METHODS Toxin-naive women (N=45) aged 30 to 50 with moderate to severe glabellar lines at maximum contraction completed the study. Five sites were treated with 4 U of onabotulinumtoxinA. Participants were assessed at day 30; those with glabellar severity of none to mild remained in the study. Participants received identical treatments at months 4, 8, 12, 16, and 20, and were assessed without treatment at 24, 25, and 26 months. RESULTS Baseline physician- and participant-rated treatment responders at maximum contraction were 84% and 80%, respectively, at month 20; and 56% and 58%, respectively, at month 26. Mean changes from physician- and participant-assessed Facial Wrinkle Scale at maximum contraction from baseline to all postbaseline measurements were significant (p≤.001). The percentage of participants reporting neutral (0) to couldn't be more satisfied (+4) with their appearance ranged from 91% to 100% during months 1 to 24. At month 26, 87% of participants reported satisfaction, with appearance scores between 0 and +4. No adverse events were reported. CONCLUSIONS OnabotulinumtoxinA delivered for 20 months significantly reduces or progressively eliminates glabellar rhytides for up to 6 months after the last treatment.

UR - http://www.scopus.com/inward/record.url?scp=79959852908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959852908&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.2011.02024.x

DO - 10.1111/j.1524-4725.2011.02024.x

M3 - Article

C2 - 21575099

AN - SCOPUS:79959852908

VL - 37

SP - 918

EP - 928

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 7

ER -